Annilicati

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		09840648
Filing Date		2001-04-23
First Named Inventor	Brian	F, Fitzpatrick
Art Unit		3622
Examiner Name		
Attorney Docket Numb	er	MRZ 8996.1

				Attorney Doo	not realized	MRZ 8996.1			
				U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	sue Date Name of Patentee or Applicant Re		Releva	Columns,Lines who nt Passages or Rel s Appear	
	1	6424951	B1	2002-07-23	Shurling et al.				
	2	6564189	B1	2003-05-13	Nycz				
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.	_	Add	_
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Name of Patentee or Applicant Rel		Releva	Columns,Lines who nt Passages or Rel s Appear		
	1								
If you wis	h to a	td additional U.S. Publ	shed An	plication citatio	n information :	please click the Ad	d button	Add	
If you wis	h to a	dd additional U.S. Publ		plication citatio		·		Add	
Examiner		dd additional U.S. Publ Foreign Document Number ³		FOREIGN PA		·	e or P		`\ ₊
If you wis	Cite	Foreign Document	Country	FOREIGN PA	Publication	Name of Patente Applicant of cited	e or P	Remove Pages, Columns, Line where Relevant Passages or Releva	`\ ₊
Examiner Initial*	Cite No	Foreign Document	Country Code ²	FOREIGN PA' / Kind i Code	Publication Date	Name of Patente Applicant of cited Document	e or P	Remove Pages, Columns, Line where Relevant Passages or Releva	`\ ₊

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature Date Considered Date Considered PEXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered, include copy of this form with next communication to applicant.

15cs Kinz Codes of USPTO Plette Documents at Invest USPTO (COL) or MEPE 90.04. * Enter of this that issued the document, by the two-letter code (NIPO Standard ST.3). **To deprese patient of courset, the reduction of the year of the right of the Emportra many precise the reside unitered for patient code.

*Kind of courset by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **Applicant is to place a check mark here if English Bangagain extrastors or attached.**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09840648
Filing Date		2001-04-23
First Named Inventor Brian		F. Fitzpatrick
Art Unit		3622
Examiner Name		
Attorney Docket Number		MRZ 8996.1

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.981	to make the	appropriate	selection(s):
---------------	----------	-----------	-------------	-------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 150(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1970(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Frank R Aggying

□ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

27 416

Signature	/Frank R. Agovino/	Date (YYYY-MM-DD)	2006-08-14

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is not lie and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. 0. 80s 1450, Alexandria, V.3.231-1450, D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, V.3.231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan Koffice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested in the contraction of the contraction of the patient o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such Adeckouse shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record vals filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to public insepections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.